Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORUVAIL vs CONCERTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the synaptic cleft. It also acts as a dopamine agonist by stimulating the release of dopamine from storage sites.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute painful shoulder (bursitis/tendinitis),Acute gouty arthritis,Juvenile idiopathic arthritis (off-label),Dysmenorrhea (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
100 to 200 mg orally twice daily
18-72 mg orally once daily in the morning, starting at 18-36 mg/day and titrating in 18 mg increments weekly; maximum 72 mg/day.
5-9 hours (terminal elimination half-life); in elderly or renal impairment, may extend up to 20 hours; clinical context: dosing adjustments recommended in renal impairment.
Terminal elimination half-life of methylphenidate from CONCERTA is approximately 3.5 hours (range 2.5-5.5 hours) in adults; in children, mean half-life is 3-4 hours. The extended-release formulation provides a prolonged clinical effect due to the OROS delivery system, not prolonged half-life.
Primarily hepatic via CYP2C9; undergoes extensive first-pass metabolism. Major metabolites include hydroxylated and carboxylated derivatives.
Primarily hepatic via deesterification to ritalinic acid (inactive). Minor pathways include hydroxylation and oxidation. Not extensively metabolized by CYP450 enzymes.
Primarily renal excretion of metabolites (60-80%) with less than 1% unchanged drug; biliary/fecal excretion accounts for 20-40%.
Primarily renal (77%-87% as unchanged drug and metabolites); metabolic elimination accounts for 13%-23%, with minor biliary excretion (<2%).
99% bound primarily to albumin.
10%-33% (mostly bound to albumin, less to alpha-1-acid glycoprotein).
0.1-0.2 L/kg; indicates low tissue distribution consistent with extensive protein binding.
Vd approximately 2.65 L/kg (range 1.3-4.6 L/kg), indicating extensive tissue distribution.
Oral: 80-100% (immediate-release); topical: approximately 5% systemic absorption.
Oral: 22% (low due to first-pass metabolism; relative bioavailability compared to immediate-release methylphenidate is 100% for total exposure, but with less peak-to-trough fluctuation).
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: contraindicated
For GFR <30 m L/min/1.73 m² or ESRD, avoid use due to accumulation of methylphenidate metabolites.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated
Child-Pugh Class C (severe impairment): reduce dose by 50%; no adjustment for Child-Pugh A or B, but monitor closely.
Not recommended for use in pediatric patients
Age ≥6 years: initial 18 mg once daily; titrate by 18 mg weekly to max 54 mg/day (6-12 years) or 72 mg/day (13-17 years); weight-based not required, but lower weight may benefit from lower starting doses.
Initiate at lowest effective dose (100 mg/day); monitor renal function and gastrointestinal bleeding risk
Start at lowest dose (18 mg daily); titrate cautiously due to increased sensitivity and higher risk of cardiovascular and psychiatric effects; monitor blood pressure and heart rate.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Oruvail is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
CONCERTA has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; use with caution in patients with asthma, pre-existing renal impairment, or hepatic impairment.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Long-term suppression of growth in children,Potential for peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome if co-administered with serotonergic drugs
Hypersensitivity to ketoprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; active GI bleeding or ulceration.
Known hypersensitivity to methylphenidate or product components,Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Severe anxiety, tension, or agitation,Tics or family history of Tourette's syndrome,Severe hypertension, heart failure, arrhythmias, or recent myocardial infarction,Hyperthyroidism
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol as it increases risk of GI bleeding. No significant food-drug interactions; however, high-fat meals may delay absorption but does not affect overall bioavailability.
Take with or without food. High-fat meals may delay absorption but do not affect overall exposure. Avoid excessive caffeine or stimulants (e.g., energy drinks) as they may potentiate side effects. Alcohol should be avoided as it can increase CNS depression and affect drug release.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trimester: Contraindicated; risk of premature ductus arteriosus closure and persistent pulmonary hypertension.
First trimester: FDA Pregnancy Category C; animal studies showed increased risk of fetal malformations (e.g., cardiovascular, skeletal) at high doses; human data insufficient to define risk. Second trimester: No specific patterns of major malformations reported in limited human studies; may be associated with fetal growth restriction. Third trimester: Increased risk of neonatal adverse effects including withdrawal (e.g., irritability, hypertonia, poor feeding) and pulmonary hypertension; use only if benefit outweighs risk.
Minimal excretion in breast milk (M/P ratio not reported). Use with caution; may cause adverse effects in neonates. Consider alternative analgesics.
Excreted into breast milk; M/P ratio not established; limited data suggest low concentrations with typical maternal doses; monitor infant for agitation, insomnia, and poor weight gain; consider risk of long-term neurodevelopmental effects; breastfeeding not recommended unless essential.
No dose adjustment recommended but avoid in 3rd trimester. Use lowest effective dose for shortest duration in 1st and 2nd trimesters.
No standard dose adjustment recommended due to limited pharmacokinetic data; continuous monitoring of clinical response and tolerability mandatory. Pregnancy-induced increases in plasma volume and renal clearance may reduce methylphenidate levels, potentially requiring increased dose if symptom control worsens. Dose titration should be cautious and individualized.
Oruvail (ketoprofen extended-release) is an NSAID with analgesic, anti-inflammatory, and antipyretic effects. Due to its extended-release formulation, it should not be crushed or chewed. Use with caution in patients with renal impairment, history of GI bleeding, or cardiovascular disease. Monitor renal function and blood pressure periodically. It inhibits platelet aggregation similarly to aspirin but is reversible. May mask signs of infection.
CONCERTA (methylphenidate HCl extended-release) uses OROS technology: 22% immediate-release (IR) followed by 78% sustained-release (SR) at a controlled rate. Do not crush, chew, or break tablets due to compromised delivery. Onset: 1–2 hours; duration: ~12 hours. Monitor for growth suppression; consider drug holidays. Avoid use with MAOIs within 14 days. QT interval prolongation risk; caution with CYP2D6 inhibitors. Discontinuation should be tapered to avoid withdrawal symptoms.
Take exactly as prescribed; do not crush or chew the capsules.,Take with food or milk to reduce stomach upset.,Avoid alcohol and other NSAIDs (including over-the-counter ibuprofen or naproxen).,Report any signs of GI bleeding (black/tarry stools, vomiting blood), unexplained weight gain, edema, or worsening kidney function (decreased urination).,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Do not use if you have a history of asthma, hives, or allergic reaction to aspirin or NSAIDs.,Inform all healthcare providers that you are taking this medication, especially before surgery.
Take once daily in the morning with or without food. Swallow whole with liquid; do not crush, chew, or split the tablet.,Do not use if you have severe anxiety, agitation, glaucoma, tics, or a family history of Tourette syndrome.,Inform your doctor of all medications, especially MAOIs, anticoagulants, antidepressants, and blood pressure drugs.,Common side effects include decreased appetite, trouble sleeping, dry mouth, headache, and stomach pain. Report chest pain, fainting, or signs of allergic reaction.,Avoid alcohol while taking Concerta. Consult your doctor before driving or operating machinery until you know how this medication affects you.,Store at room temperature, away from moisture. Keep out of reach of children.,Do not stop abruptly; dose reduction should be supervised by your physician to prevent withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORUVAIL vs CONCERTA, answered by our medical review team.
ORUVAIL is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.. CONCERTA is a CNS Stimulant that works by Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the synaptic cleft. It also acts as a dopamine agonist by stimulating the release of dopamine from storage sites.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORUVAIL and CONCERTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORUVAIL is: 100 to 200 mg orally twice daily. The standard adult dose of CONCERTA is: 18-72 mg orally once daily in the morning, starting at 18-36 mg/day and titrating in 18 mg increments weekly; maximum 72 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORUVAIL and CONCERTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORUVAIL is classified as Category C. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trime. CONCERTA is classified as Category C. First trimester: FDA Pregnancy Category C; animal studies showed increased risk of fetal malformations (e.g., cardiovascular, skeletal) at high doses; human data insufficient to de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.